Robert Goldberg

Feb 4, 2026

Duchenne Progress Shows How the FDA Should Judge Orphan Drugs

A milestone in the treatment of Duchenne muscular dystrophy (DMD) passed recently with remarkably little public notice. That silence is a sign of progress.  For years,...